Parkinson's disease (PD) is the second most common chronic progressive neurodegenerative disease worldwide, with a prevalence of more than 1% in the population over the age of 60, thus constituting a major global health problem of the aging population. The disease is primarily characterized by a major loss of nigrostriatal dopaminergic neurons but the genetic etiology leading to the neuronal cell loss has largely remained unknown. Numerous genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) that point to more than 50 genomic loci containing risk variants for sporadic PD. However the identified risk variants predominantly map to poorly understood non-coding regions of the genome, which has impeded functional and molecular understanding of how these genetic variants contribute to the increased risk for PD. Importantly, it has been established that PD GWAS associated loci are typically non-coding and mediate allele-specific effects on distal gene expression, consistent with a central role for disruption on enhancer element function in PD pathogenesis Human induced pluripotent stem cell (hiPSC) technology offers for the first time the unique opportunity to study sporadic diseases whose genetic components are poorly understood, by allowing for the generation of human patient-derived somatic cells such as midbrain dopaminergic neurons which carry all the genetic alterations that contributed to the development of the disease. The overall goal of this project is to establish a transformational paradigm, which overcomes the substantial technical limitations of the iPS system and creates a genetically defined experimental in vitro system for studying the molecular and biological mechanisms of sporadic PD in the dish. To achieve this, we will establish a novel experimental framework to link descriptive GWAS PD hits to genomic regulatory enhancer elements and establish functional assays for connecting PD risk alleles to the expression of disease relevant effector genes.
Our aim i s to gain molecular understanding of the complex interactions between multiple genetic risk alleles and to identify key genes of which the expression level affects the PD specific cellular phenotype. To identify functional relevant candidate risk variants (PD-eQLTs) we will link PD associated risk alleles to genomic regulatory (enhancer) elements that are relevant for gene activity in neurons by establishing an enhancer map in cultured homogenous dopaminergic neurons as well as in sorted neuronal nuclei from human brain. Insights into these interactions will facilitate devising rational therapeutic strategies. This experimental in vitro platform will be used to define the interactions of environmental risk factors with the genetic determinants that have been predicted from GWA studies to predispose to PD (GxE).

Public Health Relevance

Parkinson's disease (PD) is the second most common chronic progressive neurodegenerative disease worldwide, with a prevalence of more than 1% in the population over the age of 60, thus constituting a major global health problem of the aging population. While genome-wide association studies (GWAS) have pointed to more than 50 genomic loci that contribute to the risk of PD, little functional and molecular understanding has been gained into which and how these genetic variants contribute to the increased risk for PD, and this lack of insight has impeded the development of rational therapeutic strategies. The overall goal of this project is to establish a genetically defined experimental in vitro system for studying the molecular and biological mechanisms of sporadic PD in the dish and to identify novel genes that are causally involved in the pathogenesis of Parkinson's.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS088538-03
Application #
9112027
Study Section
Molecular Neurogenetics Study Section (MNG)
Program Officer
Sutherland, Margaret L
Project Start
2014-09-23
Project End
2019-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
120989983
City
Cambridge
State
MA
Country
United States
Zip Code
Cohen, Malkiel A; Markoulaki, Styliani; Jaenisch, Rudolf (2018) Matched Developmental Timing of Donor Cells with the Host Is Crucial for Chimera Formation. Stem Cell Reports 10:1445-1452
Roessler, Reinhard; Goldmann, Johanna; Shivalila, Chikdu et al. (2018) JIP2 haploinsufficiency contributes to neurodevelopmental abnormalities in human pluripotent stem cell-derived neural progenitors and cortical neurons. Life Sci Alliance 1:e201800094
Liu, X Shawn; Wu, Hao; Krzisch, Marine et al. (2018) Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. Cell 172:979-992.e6
Ma, Haiting; Wert, Katherine J; Shvartsman, Dmitry et al. (2018) Establishment of human pluripotent stem cell-derived pancreatic ?-like cells in the mouse pancreas. Proc Natl Acad Sci U S A 115:3924-3929
Sahakyan, Anna; Kim, Rachel; Chronis, Constantinos et al. (2017) Human Naive Pluripotent Stem Cells Model X Chromosome Dampening and X Inactivation. Cell Stem Cell 20:87-101
Edupuganti, Raghu Ram; Harikumar, Arigela; Aaronson, Yair et al. (2017) Alternative SET/TAFI Promoters Regulate Embryonic Stem Cell Differentiation. Stem Cell Reports 9:1291-1303
Weintraub, Abraham S; Li, Charles H; Zamudio, Alicia V et al. (2017) YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell 171:1573-1588.e28
Oh, Chang-Ki; Sultan, Abdullah; Platzer, Joseph et al. (2017) S-Nitrosylation of PINK1 Attenuates PINK1/Parkin-Dependent Mitophagy in hiPSC-Based Parkinson's Disease Models. Cell Rep 21:2171-2182
Harikumar, Arigela; Edupuganti, Raghu Ram; Sorek, Matan et al. (2017) An Endogenously Tagged Fluorescent Fusion Protein Library in Mouse Embryonic Stem Cells. Stem Cell Reports 9:1304-1314
Labadorf, Adam; Choi, Seung H; Myers, Richard H (2017) Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles. Front Mol Neurosci 10:430

Showing the most recent 10 out of 29 publications